Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Myotonic Dystrophy Drug Market by Type (ISIS-DMPKRx, PRO-135, SRT-152, VAL-0411, Others), By Application (Hospital, Clinic, Home Use, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Myotonic Dystrophy Drug Market by Type (ISIS-DMPKRx, PRO-135, SRT-152, VAL-0411, Others), By Application (Hospital, Clinic, Home Use, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 320119 4200 Pharma & Healthcare 377 147 Pages 4.7 (40)
                                          

Market Overview:


The global myotonic dystrophy drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of myotonic dystrophy, rising awareness about myotonic dystrophy drugs, and increasing R&D investments for the development of new drugs. The global myotonic dystrophy drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into ISIS-DMPKRx, PRO-135, SRT-152, VAL-0411 and others. On the basis of application, the market is segmented into hospital use, clinic use and home use. The regional segments are North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (Japan China India Australia) Middle East & Africa(South Africa Saudi Arabia UAE).


Global Myotonic Dystrophy Drug Industry Outlook


Product Definition:


Myotonic dystrophy (DM) is a genetic disorder that affects muscle function. The hallmark symptom of DM is muscle weakness, which can progress to complete paralysis. There is no cure for DM and there are currently no treatments that can reverse or stop its progression. Myotonic dystrophy drug is used to improve the quality of life for people with this condition by helping them to maintain their muscle strength and mobility for as long as possible.


ISIS-DMPKRx:


ISIS-DMPKRx is a drug developed by Ionis Pharmaceuticals, Inc. (previously Isis Pharmaceuticals, Inc.) for the treatment of myotonic dystrophy type 2 (MD-2). It is an RNAi therapeutic designed to reduce levels of DMPK in the body by inhibiting its production and activity. The drug has completed phase 2 clinical trials and was granted fast track designation for its approval process in 2015.


PRO-135:


PRO-135 is a drug that improves the ability of muscles to retain sodium and chloride. It is used in treating Myotonic Dystrophy (MD). The global market for MD drugs has been growing rapidly over the past few years, as there have been several developments in treatment options available for this progressive disorder.


Application Insights:


The clinic use segment dominated the global market in 2017. This is due to factors such as high unmet medical need and the presence of a large patient base waiting for treatment. Moreover, increasing awareness about myotonic dystrophy among patients and healthcare professionals is expected to boost demand over the forecast period.


The hospital use segment held a significant share owing to factors such as advanced disease stage at diagnosis, frequent hospitalization required for supportive care along with drug therapy management which requires constant monitoring and skilled personnel attendance.


Regional Analysis:


North America dominated the global market in 2017. The presence of a large number of players coupled with high R&D investment by them is one of the major factors responsible for its dominance. Moreover, increasing government funding and initiatives to create awareness about this disease are also expected to drive the regional market over the forecast period. For instance, in September 2016, Fycompa received approval from U.S FDA for expanded application as an add-on therapy with methotrexate in adults with active myotonic dystrophy who have not responded after 6 months or more stable on MTX therapy (labeled indication).


Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing healthcare expenditure and growing patient awareness levels regarding novel treatment options for rare diseases such as myotonic dystrophy which have very few effective therapies available commercially available worldwide.


Growth Factors:


  • Increasing prevalence of myotonic dystrophy
  • Growing awareness about myotonic dystrophy
  • Rising demand for effective treatment options for myotonic dystrophy
  • Availability of government funding for research on myotonic dystrophy drugs
  • Technological advancements in the field of drug development

Scope Of The Report

Report Attributes

Report Details

Report Title

Myotonic Dystrophy Drug Market Research Report

By Type

ISIS-DMPKRx, PRO-135, SRT-152, VAL-0411, Others

By Application

Hospital, Clinic, Home Use, Others

By Companies

BioMarin Pharmaceutical Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, Isis Pharmaceuticals, Inc., Marina Biotech, Inc., Valentia Biopharma S.L., BioMarin Pharmaceutical Inc.

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

147

Number of Tables & Figures

103

Customization Available

Yes, the report can be customized as per your need.


Global Myotonic Dystrophy Drug Market Report Segments:

The global Myotonic Dystrophy Drug market is segmented on the basis of:

Types

ISIS-DMPKRx, PRO-135, SRT-152, VAL-0411, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Clinic, Home Use, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. BioMarin Pharmaceutical Inc.
  2. F. Hoffmann-La Roche Ltd.
  3. Genzyme Corporation
  4. Isis Pharmaceuticals, Inc.
  5. Marina Biotech, Inc.
  6. Valentia Biopharma S.L.
  7. BioMarin Pharmaceutical Inc.

Global Myotonic Dystrophy Drug Market Overview


Highlights of The Myotonic Dystrophy Drug Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. ISIS-DMPKRx
    2. PRO-135
    3. SRT-152
    4. VAL-0411
    5. Others
  1. By Application:

    1. Hospital
    2. Clinic
    3. Home Use
    4. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Myotonic Dystrophy Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Myotonic Dystrophy Drug Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Myotonic Dystrophy Drug is a medication prescribed to help control the symptoms of myotonic dystrophy. Myotonic dystrophy is a rare genetic disorder that causes muscle weakness and difficulty moving muscles. Myotonic dystrophy drug helps to improve muscle strength, movement, and function.

Some of the major companies in the myotonic dystrophy drug market are BioMarin Pharmaceutical Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, Isis Pharmaceuticals, Inc., Marina Biotech, Inc., Valentia Biopharma S.L., BioMarin Pharmaceutical Inc..

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Myotonic Dystrophy Drug Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Myotonic Dystrophy Drug Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Myotonic Dystrophy Drug Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Myotonic Dystrophy Drug Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Myotonic Dystrophy Drug Market Size & Forecast, 2020-2028       4.5.1 Myotonic Dystrophy Drug Market Size and Y-o-Y Growth       4.5.2 Myotonic Dystrophy Drug Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 ISIS-DMPKRx
      5.2.2 PRO-135
      5.2.3 SRT-152
      5.2.4 VAL-0411
      5.2.5 Others
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Clinic
      6.2.3 Home Use
      6.2.4 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Myotonic Dystrophy Drug Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Myotonic Dystrophy Drug Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 ISIS-DMPKRx
      9.6.2 PRO-135
      9.6.3 SRT-152
      9.6.4 VAL-0411
      9.6.5 Others
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Clinic
      9.10.3 Home Use
      9.10.4 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 ISIS-DMPKRx
      10.6.2 PRO-135
      10.6.3 SRT-152
      10.6.4 VAL-0411
      10.6.5 Others
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Clinic
      10.10.3 Home Use
      10.10.4 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 ISIS-DMPKRx
      11.6.2 PRO-135
      11.6.3 SRT-152
      11.6.4 VAL-0411
      11.6.5 Others
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Clinic
      11.10.3 Home Use
      11.10.4 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 ISIS-DMPKRx
      12.6.2 PRO-135
      12.6.3 SRT-152
      12.6.4 VAL-0411
      12.6.5 Others
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Clinic
      12.10.3 Home Use
      12.10.4 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 ISIS-DMPKRx
      13.6.2 PRO-135
      13.6.3 SRT-152
      13.6.4 VAL-0411
      13.6.5 Others
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Clinic
      13.10.3 Home Use
      13.10.4 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Myotonic Dystrophy Drug Market: Competitive Dashboard
   14.2 Global Myotonic Dystrophy Drug Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 BioMarin Pharmaceutical Inc.
      14.3.2 F. Hoffmann-La Roche Ltd.
      14.3.3 Genzyme Corporation
      14.3.4 Isis Pharmaceuticals, Inc.
      14.3.5 Marina Biotech, Inc.
      14.3.6 Valentia Biopharma S.L.
      14.3.7 BioMarin Pharmaceutical Inc.

Our Trusted Clients

Contact Us